Crystalline form of tenofovir disoproxil and a process for its preparation
Crystalline Form C of tenofovir disoproxil, salts thereof and a process for its preparation. The process involves adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water, whereby the crystalline Form C of tenofovir disoproxil precipitates. The crystalline Form C of tenofovir disoproxil may be converted to a salt thereof. There is also provided a process for purifying a crude product comprising tenofovir monoisoproxil and tenofovir disoproxil.
1. Crystalline Form C of tenofovir disoproxil characterised as having an XRPD pattern comprising peaks at 6.8, 23.2, 25.5 and 31.7°2θ±0.2°2θ.
2. Crystalline Form C of tenofovir disoproxil according to claim 1 , characterised in that the XRPD pattern comprises further peaks at 8.3, 17.4, 18.7 and 22.9°2θ±0.2°2θ.
3. Crystalline Form C of tenofovir disoproxil according to claim 1 , characterised as having an XRPD pattern as shown in FIG. 1 .
4. Crystalline Form C of tenofovir disoproxil according to claim 1 , having a melting point ranging from 61°C. to 66°C.
5. Crystalline Form C of tenofovir disoproxil according to claim 1 , characterised as having a DSC pattern as shown in FIG. 2 .
6. Crystalline Form C of tenofovir disoproxil according to claim 1 , containing less than 0.2% tenofovir monoisoproxil.
7. A process for preparing crystalline Form C of tenofovir disoproxil or a salt thereof, the process comprising adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water, cooling the solution to a temperature below 0° C., whereby the crystalline Form C of tenofovir disoproxil having an XRPD pattern comprising peaks at 6.8, 23.2, 25.5 and 31.7°±0.2°precipitates, and optionally converting the crystalline Form C of tenofovir disoproxil to a salt of crystalline Form C of tenofovir disoproxil.
8. The process according to claim 7 , wherein the salt-saturated water is water saturated with an alkali or alkaline earth metal salt.
9. The process according to claim 7 , wherein the salt-saturated water is water saturated with sodium chloride.
10. The process according to claim 7 , wherein the organic solvent is a water miscible organic solvent.
11. The process according to claim 7 , wherein the organic solvent is N-methyl pyrrolidone or dimethyl sulfoxide.
12. The process according to claim 7 , wherein the aqueous solution comprising the tenofovir disoproxil is cooled to a temperature below −10° C.
13. The process according to claim 7 , wherein the crystalline Form C of tenofovir disoproxil is converted to the fumarate salt of crystalline Form C of tenofovir disoproxil.
14. The process according to according to claim 7 , wherein the solution of the tenofovir disoproxil in the organic solvent is the reaction mass resulting from a synthesis of the tenofovir disoproxil.
15. The process according to claim 14 , wherein the tenofovir disoproxil is synthesised by condensing 9-[2-(R)-(phosphonomethoxy)propyl]adenine with chloromethyl isopropyl carbonate in the organic solvent and in the presence of triethyl amine.
16. The process according to claim 7 , wherein the solution of tenofovir disoproxil is prepared by dissolving crude tenofovir disoproxil or any crystalline form of tenofovir disoproxil in the organic solvent.
17. The process according to claim 7 , wherein an amount of monoisoproxil impurity in the Form C product is present in an amount less than 1%.
18. The process according to claim 17 , wherein the amount of monoisoproxil impurity in the Form C product is present in an amount less than 0.2%.